tbuckley/cabot-search huggingface dataset:
Novel skin patch combining human fibroblast-derived matrix and ciprofloxacin for infected wound healing
Authors: Muhammad Suhaeri, Mi Hee Noh, Ji-Hoi Moon, In Gul Kim, Seung Ja Oh, Sang Su Ha, Jong Ho Lee, Kwideok Park
Journal: Theranostics (2018)

Skin injuries are frequently encountered in daily life, but deep wounds often poorly self-heal and do not recover completely. In this study, we propose a novel skin patch that combines antibiotic, cell-derived extracellular matrix (ECM) and biocompatible polyvinyl alcohol (PVA) hydrogel. Methods: Decellularized human lung fibroblast-derived matrix (hFDM) was prepared on tissue culture plate (TCP) and PVA solution was then poured onto it. After a freeze-thaw process, PVA was peeled off from TCP along with hFDM tightly anchored to PVA. Subsequently, ciprofloxacin (Cipro)-incorporated PVA/hFDM (PVA/Cipro/hFDM) was fabricated via diffusion-based drug loading. Results: In vitro analyses of PVA/Cipro/hFDM show little cytotoxicity of ciprofloxacin, stability of hFDM, rich fibronectin in hFDM, and good cell attachment, respectively. In addition, hFDM proved to be beneficial in promoting cell migration of dermal fibroblasts and human umbilical vein endothelial cells (HUVECs) using transwell inserts. The antibacterial drug Cipro was very effective in suppressing colony growth of gram-negative and -positive bacteria as identified via an inhibition zone assay. For animal study, infected wound models in BALB/c mice were prepared and four test groups (control, PVA, PVA/Cipro, PVA/Cipro/hFDM) were administered separately and their effect on wound healing was examined for up to 21 days. The results support that Cipro successfully reduced bacterial infection and thus encouraged faster wound closure. Further analysis using histology and immunofluorescence revealed that the most advanced skin regeneration was achieved with PVA/Cipro/hFDM, as assessed via re-epithelialization, collagen texture and distribution in the epidermis, and skin adnexa (i.e., glands and hair follicles) regeneration in the dermis. Conclusion: This work demonstrates that our skin patch successfully consolidates the regenerative potential of ECM and the antibacterial activity of Cipro for advanced wound healing.
Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor induction in checkpoint inhibitor resistant metastatic melanoma patients
Authors: T.H. Borch, R. Andersen, M.A.H. Rana, P. Kongsted, M. Pedersen, M. Nielsen, J.W. Kjeldsen, A. Kverneland, C.L. Lorentzen, Ö Met, M. Donia, I.M. Svane
Journal: Annals of Oncology (2018)
P2.04-13 The Immune Checkpoint, HVEM Contribute to Immune Escape in Non Small Cell Lung Cancer of Lacking PDL1 Expression
Authors: S. Ren, H. Yu, C. Rivard, K. Suda, C. Caldwell, L. Rozeboom, T. Ng, G. Rivalland, P. Mitchell, C. Zhou, F. Hirsch
Journal: Journal of Thoracic Oncology (2018)
OA12.03 Activity of Crizotinib in MET or ROS1 Positive (+) NSCLC: Results of the AcSé Trial.
Authors: D. Moro-Sibilot, N. Cozic, M. Pérol, J. Otto, J. Mazieres, P. Souquet, R. Bahleda, M. Wislez, S. De Guibert, B. Mennecier, C. Chouaid, R. Sabatier, S. Bota, R. Gervais, V. Verriele, V. Haddad, G. Ferretti, F. Nowak, C. Mahier - Ait Oukhatar, G. Vassal
Journal: Journal of Thoracic Oncology (2018)
Gut microbiota and intestinal FXR mediate the clinical benefits of metformin
Authors: Lulu Sun, Cen Xie, Guang Wang, Yue Wu, Qing Wu, Xuemei Wang, Jia Liu, Yangyang Deng, Jialin Xia, Bo Chen, Songyang Zhang, Chuyu Yun, Guan Lian, Xiujuan Zhang, Heng Zhang, William H. Bisson, Jingmin Shi, Xiaoxia Gao, Pupu Ge, Cuihua Liu, Kristopher W. Krausz, Robert G. Nichols, Jingwei Cai, Bipin Rimal, Andrew D. Patterson, Xian Wang, Frank J. Gonzalez, Changtao Jiang
Journal: Nature Medicine (2018)
Prognostic value of response according to tumour growth rate in a phase I trial on vaccine therapy
Authors: A. Bellucci, C. Nevoret, C. De Bazelaire, S. Oudard, L.O. Teixeira, R. Defrance, T. Huet, L.D. Pierre, V. Doppler, J. Medioni, S. Culine, L. Fournier
Journal: Annals of Oncology (2018)
P1.03-27 Somatic Mutations in BRCA2 Genes Are Associated with Prognosis in Chinese Non-Small-Cell Lung Cancer Patients
Authors: J. Lai, C. Xu, W. Wang, Q. Zhang, W. Zhuang, Y. Zhu, Y. Huang, Y. Chen, G. Chen, M. Fang, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2018)
Modelling the role of microbial p-cresol in colorectal genotoxicity
Authors: Eiman Abdulla Al Hinai, Piyarach Kullamethee, Ian R. Rowland, Jonathan Swann, Gemma E. Walton, Daniel M. Commane
Journal: Gut Microbes (2018)

Background A greater understanding of mechanisms explaining the interactions between diet and the gut microbiota in colorectal cancer is desirable. Genotoxic microbial metabolites present in the colon may be implicated in carcinogenesis and potentially influenced by diet.Aims We hypothesised that microbial p-cresol is a colonic genotoxin and set out to model potential exposures in the colon and the effects of these exposures on colonic cells.Methods Batch culture fermentations with human faecal inoculate were used to determine the synthesis of p-cresol and other metabolites in response to various substrates. The fermentation supernatants were evaluated for genotoxicity and the independent effects of p-cresol on colonic cells were studied in vitro.Results In batch culture fermentation, supplementary protein increased the synthesis of phenols, indoles and p-cresol, whereas supplementary fructoligosaccharide (FOS) increased the synthesis of short chain fatty acids. The p-cresol was the greatest predictor of genotoxicity against colonocytes in the fermentation supernatants. Spiking fermentation supernatants with exogenous p-cresol further increased DNA damage, and independently p-cresol induced DNA damage in a dose-dependent manner against HT29 and Caco-2 cells and influenced cell cycle kinetics.Conclusions In the colon p-cresol may reach physiologically significant concentrations which contribute to genotoxic exposures in the intestinal lumen, p-cresol production may be attenuated by substrate, and therefore diet, making it a potential modifiable biomarker of genotoxicity in the colon.
A novel biomarker combination and its association with resistance to chemotherapy combinations with bevacizumab: First results of the PERMAD trial
Authors: T. Seufferlein, L. Lausser, A. Stein, G. Prager, S. Kasper, M. Niedermeier, L. Müller, S. Kubicka, A.-O. König, P. Büchner-Steudel, K. Wille, L. Perkhofer, A. Hann, A.W. Berger, D. Arnold, H. Kestler, T.J. Ettrich
Journal: Annals of Oncology (2018)
Ramosetron versus palonosetron in combination with aprepitant and dexamethasone for the control of highly emetogenic chemotherapy-induced nausea and vomiting
Authors: J.H. Kwon, J.-H. Kang, Y.-G. Lee, K.U. Park, H.J. An, J. Sohn, Y.M. Seol, H. Lee, H.-J. Yun, J.S. Ahn, H.J. Kim
Journal: Annals of Oncology (2018)
Phase II/III study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1/3 mRNA expression
Authors: C.N. Sternberg, J. Bellmunt, H. Nishiyama, D.P. Petrylak, D.I. Quinn, K. Nakajima, C. Lu, A. Holynskyj
Journal: Annals of Oncology (2018)
Health-related quality of life (HRQoL) for octreotide long-acting (oct l-a) vs. placebo (PBO) in patients (pts) with metastatic midgut neuroendocrine tumors (mmNETs) in the phase IIIb PROMID trial
Authors: A. Rinke, M.P. Neary, J. Eriksson, M. Hunger, T. Doan, D. Karli, R. Arnold
Journal: Annals of Oncology (2018)
P3.04-03 Association of Functional Polymorphism in CTLA-4 Gene with Survival in Non-Small Cell Lung Cancer: A Brazilian Study
Authors: J. Machado-Rugolo, A. Fabro, E. Cuentas, V. De Sá, C. Rainho, M. Nagai, V. Capelozzi, M. Balancin
Journal: Journal of Thoracic Oncology (2018)
Trilaciclib (T) decreases multi-lineage myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy
Authors: K.H. Dragnev, T.K. Owonikoko, T. Csoszi, M. Maglakelidze, J.T. Beck, M. Domine Gomez, A. Lowczak, A. Fulop, R.J. Hoyer, W. Hanna, P. Lowry, R. Aljumaily, V.K. Chiu, I. Bulat, Z. Yang, P.J. Roberts, J.M. Antal, R.K. Malik, S.R. Morris, J.M. Weiss
Journal: Annals of Oncology (2018)
A randomized phase II study of cisplatin plus radiotherapy versus durvalumab plus radiotherapy followed by adjuvant durvalumab versus durvalumab plus radiotherapy followed by adjuvant tremelimumab and durvalumab in intermediate risk, HPV-positive, locoregionally advanced oropharyngeal squamous cell cancer (LA-OSCC) (Canadian Cancer Trials Group HN.9)
Authors: A. Spreafico, K. Sultanem, B. Chen, S.V. Bratman, J. Ringash, A.V. Louie, A. McNiven, K. Whelan, J. Hilton, J. Yoo, J.-P. Machiels, L.F. Licitra, S. Oosting, J.N. Waldron, L.L. Siu, W.R. Parulekar
Journal: Annals of Oncology (2018)
Promoting Role of MXene Nanosheets in Biomedical Sciences: Therapeutic and Biosensing Innovations
Authors: Mohammadreza Soleymaniha, Mohammad‐Ali Shahbazi, Ali Reza Rafieerad, Aziz Maleki, Ahmad Amiri
Journal: Advanced Healthcare Materials (2018)

Abstract MXene nanosheets have emerged as biocompatible transition metal structures, which illustrate desirable performance for various applications due to their unique structural, physicochemical, and compositional features. MXenes are currently expanding their usage territory from mechanical, optical, chemical, and electronic fields toward biomedical areas. This is mainly originated from their large surface area and strong absorbance in near‐infrared region, which in combination with their facile surface functionalization with various polymers or nanoparticles, make them promising nanoplatforms for drug delivery, cancer therapy, precise biosensing and bioimaging. The facile surface modification of the MXenes can mediate the better in vivo performance of them through reduced toxicity, enhanced colloidal stability, and extended circulation within the body. Herein, the synthesis and state‐of‐the‐art progresses of MXene nanosheets designed for biomedical applications, including structural‐ and dose‐dependent antimicrobial activity, photothermal therapy, drug delivery, and implants are emphasized. Furthermore, biosensing applications are highlighted and a comprehensive discussion on photoacoustic imaging, magnetic resonance imaging, computed tomography imaging, and optical imaging of MXenes is presented. The challenges and future opportunities of applying MXene nanomaterials in the area of biomedicine are also discussed.
P2.03-22 OCT4andSOX2 Specific CTLs Plus PD-1 Inhibitor Had Synergistic Effect on Killing CSC And Treating Drug-Resistant Lung Cancer Mice
Authors: X. Zhang, F. Hu, X. Zheng, B. Zhang, H. Wang, G. Tao, J. Xu, Y. Zhang, B. Han
Journal: Journal of Thoracic Oncology (2018)
Pembrolizumab in patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC): The phase II KEYNOTE-629 study
Authors: L.F. Licitra, L.L. Siu, E.E.W. Cohen, P. Zhang, B. Gumuscu, R. Swaby, K. Harrington
Journal: Annals of Oncology (2018)
P1.13-35 Hypoxia Mapping Using Oxygen-Enhanced MRI in Lung Cancer
Authors: A. Salem, R. Little, M. Babur, A. Featherstone, I. Peset, S. Cheung, Y. Watson, V. Tessyman, H. Mistry, G. Ashton, C. Behan, J. Matthews, M. Asselin, R. Bristow, A. Jackson, K. Williams, G. Parker, C. Faivre-Finn, J. O’Connor
Journal: Journal of Thoracic Oncology (2018)
P2.04-09 Driver Mutations are Associated with Distinct Patterns of Response to Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
Authors: M. Negrao, A. Reuben, J. Robichaux, X. Le, M. Nilsson, Y. Elamin, C. Wu, J. Zhang, L.L. Landry, E. Roarty, W. Rinsurongkawong, S. Swisher, G. Simon, P.A. Futreal, B. Glisson, J. Zhang, J. Heymach
Journal: Journal of Thoracic Oncology (2018)
P1.16-14 Impact of Smoking on Treatment Outcome in Early Squamous Cell Lung Cancer (T1N0)
Authors: J. Lee, T.H. Kim, B.J. Park, J.H. Cho, H.K. Kim, Y.S. Choi, J.I. Zo, Y.M. Shim, J. Kim
Journal: Journal of Thoracic Oncology (2018)
Chronic unilateral nasal congestion
Authors: Zhenxiao Huang, Jingying Ma, Bing Zhou
Journal: BMJ (2018)

An 18 year old man was referred to the otolaryngology (head and neck surgery) department with persistent right sided nasal congestion for one year. He had used a nasal corticosteroid spray in the six months before presentation, but his symptoms had not improved.

At the otolaryngology department he underwent a non-contrast computed tomography scan of his sinuses (fig 1). What is the diagnosis?



Fig 1 
Computed tomography scans of the sinuses (coronal planes)



Antrochoanal polyps (ACPs) in the right sinonasal cavity (fig 2).



Fig 2 
Computed …
P2.01-50 Thromboembolism in ROS1 Rearranged Non-Small Cell Lung Cancer
Authors: M. Itchins, M. Alexander, T. John, S. Kao, B. Hughes, S. Hayes, V. Howell, R. Harvie, S. Clarke, M. Millward, N. Pavlakis, A. Lee
Journal: Journal of Thoracic Oncology (2018)
Gastric Cancer Etiology and Management in Asia and the West
Authors: Ashley E. Russo, Vivian E. Strong
Journal: Annual Review of Medicine (2018)

Regional variation in treatment paradigms for gastric adenocarcinoma has attracted a great deal of interest. Between Asia and the West, major differences have been identified in tumor biology, implementation of screening programs, extent of surgical lymphadenectomy, and routine use of neoadjuvant versus adjuvant treatment strategies. Minimally invasive techniques, including both laparoscopic and robotic platforms, have been studied in both regions, with attention to safety, feasibility, and long-term oncologic outcomes. The purpose of this review is to discuss advances in the understanding of the etiology and underlying biology of gastric cancer, as well as the current state of management, focusing on the differences between Asia and the West.
P2.03-14 PKCi-PAK1 Pathway Modulates Sensitivity to Therapy in EGFR, KRAS Mutant and Squamous Cell Non-Small Cell Lung Cancer (NSCLC)
Authors: M. Ito, C. Codony-Servat, J. Codony-Servat, I. Attili, J. Berenguer, J. Bracht, N. Gil, M. Okada, N. Karachaliou, P. Cao, R. Rosell
Journal: Journal of Thoracic Oncology (2018)
P2.09-26 Clinical Significance of Subcellular Localization of Maspin in Patients with Pathological Stage IA Lung Adenocarcinoma
Authors: T. Ohno, Y. Nosaka, W. Fujiwara, T. Miyamoto, T. Kadonaga, Y. Kidokoro, M. Wakahara, Y. Takagi, Y. Tanaka, T. Haruki, K. Miwa, Y. Suzuki, Y. Taniguchi, H. Nakamura, Y. Umekita
Journal: Journal of Thoracic Oncology (2018)
Prognostic factors in patients with uterine leiomyosarcoma: A multiinstitutional retrospective study from the Japanese gynecologic oncology group
Authors: K. Takehara, N. Yamashita, T. Motohashi, K. Harano, T. Nakanishi, H. Tokunaga, N. Susumu, Y. Ueda, Y. Yokoyama, Y. Watanabe, R. Watanabe, N. Teramoto, H. Tsuda, T. Saito
Journal: Annals of Oncology (2018)
The impact of the 21 gene recurrence score (RS) on chemotherapy (CHemoRx) prescribing in hormone receptor (HR) positive, lymph node positive (LN+) early-stage breast cancer (BC) in Ireland: A national, multi-centre, prospective study (CTRIAL-IE 15-34)
Authors: A. Hassan, N. Keegan, C. O’Leary, L. McSorley, T. Mahgoub, S. O’Reilly, J. Walshe, M.J. Kennedy, L. Coate, M. O’Connor, M. Keane, C.M. Kelly, M. Milewski, S. Molloy, K. Eagan, V. Murphy, O.S. Breathnach, L. Grogan, B. Hennessy, P.G. Morris
Journal: Annals of Oncology (2018)
MA27.09 Dual Inhibition of BCL-XL and MCL-1 is Required to Induce Tumour Regression in Lung Squamous Cell Carcinomas Sensitive to FGFR Inhibition
Authors: C. Weeden, C. Ah-Cann, A. Holik, D. Merino, G. Lessene, M. Asselin-Labat
Journal: Journal of Thoracic Oncology (2018)
Abstract 17979: Nurse Practitioners Recognize, Address Depression-cardiovascular Disease in Older Adults
Authors: Lorraine M Novosel, Salina A Smialek
Journal: Circulation (2015)

Depression is a risk factor for as well as a comorbidity of cardiovascular disease (CVD) in older adults (OA). Providers must target efforts toward the prevention, recognition, diagnosis, and treatment of depression to reduce CVD burden and morbidity and mortality among our rapidly growing aging population. While the AHA recommends routine screening for depression in all individuals with heart disease and the scientific community considers elevating depression to the status of "formal" CVD risk factor, depression remains under-diagnosed and sub-optimally treated by cardiology and primary care physicians. Nurse practitioners (NPs), utilizing a biopsychosocial model of care have a significant role in screening, health promotion, and risk reduction efforts and are positioned to play a vital role in primary care. This mixed-method study explored NPs’ knowledge, screening and risk reduction behaviors related to depression-CVD in OA. We hypothesized that NPs integrate depression screening, diagnosis and treatment into CVD risk reduction and management. Methods. A national sample of NPs (N=118) completed an anonymous survey. A subset (n=12) participated in a follow-up interview. Results: The NPs were aware of the high prevalence of depression among OA with CVD and identified depression as a risk for CVD. One-half were unaware of the AHA recommendation for depression screening or Medicare depression screening and cardiovascular preventive services. Yet, 70% routinely screened their OA patients, and OA patients with CVD for depression. The NPs (92.7%) were confident in their ability to address classic CVD risks and stressed the importance of a quality patient relationship to optimize depression care. A majority (64%) felt it would be at least “somewhat” easy to incorporate depression into their routine CVD risk reduction practices if depression became a “formal” CVD risk factor. Inadequate counseling skills and lack of mental health resources were cited as challenges. Conclusions. NPs are confident in their ability to promote CVD risk reduction among their OA patients and recognize and address depression in cardiovascular care. They are prepared to incorporate depression into CVD risk reduction practice but lack depression counseling resources.
Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): A focus on the EMBRACA triple negative (TNBC) subpopulation
Authors: H.S. Rugo, R. Quek, J. Ettl, S.A. Hurvitz, H. Bhattacharyya, A.L. Hannah, J.K. Litton
Journal: Annals of Oncology (2018)
Baseline blood immune profiling to predict response to antiPD-1 in patients with advanced non-small cell lung cancer
Authors: E. Romano, T. Le Bourgeois, S. Lopez-Lastra, V. Servois, S. Beaucaire-Danel, C. Daniel, J.-Y. Pierga, F.-C. Bidard, O. Lantz
Journal: Annals of Oncology (2018)
Reply to “Comment on ‘Association of subungual melanoma and subungual squamous cell carcinoma: A case series’”
Authors: Amélie Boespflug, Sébastien Debarbieux, Lauriane Depaepe, Brigitte Chouvet, Delphine Maucort-Boulch, Stéphane Dalle, Brigitte Balme, Luc Thomas
Journal: Journal of the American Academy of Dermatology (2018)
Clinical outcomes in patients (pts) with estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC) with objective response (OR) or without objective response (non-OR) in PALOMA-2
Authors: H.S. Rugo, R.S. Finn, K.A. Gelmon, A.A. Joy, O.N. Lipatov, N. Harbeck, A. Castrellon, H. Mukai, J.M. Walshe, A. Mori, E. Gauthier, D.R. Lu, E. Bananis, M. Martín, V. Dieras
Journal: Annals of Oncology (2018)
MA23.03 Risk Assessment for Indeterminate Pulmonary Nodules Using a Novel, Plasma-Protein Based Biomarker Assay
Authors: A. Fish, A. Vachani, M. Beggs, L. Carbonell, Z. Haddad, A. Juang, S. Kamer, B. Patel, H. Yu, A. Wu, P. Massion, M. Arjomandi, J. Brown, N. Trivedi, T. Rubenstein
Journal: Journal of Thoracic Oncology (2018)
The prognostic value of the proportion and subtype patterns of intraductal carcinoma of the prostate in patients with de novo metastatic prostate cancer: A propensity score matching study
Authors: J. Zhao, J. Liu, G. Sun, P. Shen, J. Chen, X. Zhang, H. Zhang, Z. Liu, Y. Bao, Y. Yang, P. Zhao, K. Shu, H. Zeng
Journal: Annals of Oncology (2018)
P2.06-25 Combined Immune Checkpoint Blockade in Malignant Pleural Mesothelioma: In Vivo Validation of in Vitro Results
Authors: E. Marcq, J. De Waele, J. Van Audenaerde, J. Jacobs, J. Van Loenhout, P. Pauwels, E. Smits, J. Van Meerbeeck
Journal: Journal of Thoracic Oncology (2018)
Pre-specified interim analysis of a randomized phase IIb trial of trastuzumab + nelipeptimut-S (NeuVax) vs trastuzumab for the prevention of recurrence demonstrates benefit in triple negative (HER2 low-expressing) breast cancer patients
Authors: D.F. Hale, E.A. Mittendorf, T.A. Brown, G.T. Clifton, T.J. Vreeland, J. Myers, K. Peace, D. Jackson, J. Greene, J. Holmes, G.E. Peoples
Journal: Annals of Oncology (2018)
P1.13-43 Molecular and Imaging Predictors of Response to Ado-Trastuzumab Emtansine in Patients with HER2 Mutant Lung Cancers: An Exploratory Phase 2 Trial
Authors: B. Li, M. Offin, T. Hembrough, F. Cecchi, R. Shen, Z. Olah, E. Panora, M. Myers, E. Brzostowski, D. Buonocore, M. Ginsberg, C. Rudin, M. Kris, G. Weitsman, P. Barber, T. Ng, G. Ulaner, M. Arcila, M. Scaltriti
Journal: Journal of Thoracic Oncology (2018)
PERNETTA: A non-comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207)
Authors: J. Huober, P. Weder, C. Veyret, B. Thürlimann, A. Xyrafas, L. Vanlemmens, S. Guiu, E. Brain, J. Grenier, F. Dalenc, C. Levy, A.M. Savoye, A. Müller, V. Membrez-Antonioli, M.A. Gerard, J. Lemonnier, H. Hawle, E. Boven, H. Bonnefoi
Journal: Annals of Oncology (2018)
Overexpression of HOXC10 promotes angiogenesis in human glioma via interaction with PRMT5 and upregulation of VEGFA expression
Authors: Zhanyao Tan, Kun Chen, Wenjiao Wu, Yanqing Zhou, Jinrong Zhu, Geyan Wu, Lixue Cao, Xin Zhang, Hongyu Guan, Yi Yang, Wei Zhang, Jun Li
Journal: Theranostics (2018)

High levels of angiogenesis are associated with poor prognosis in patients with gliomas. However, the molecular mechanisms underlying tumor angiogenesis remain unclear. Methods: The effect of homeobox C10 (HOXC10) on tube formation, migration, and proliferation of human umbilical vein endothelial cells (HUVECs) and on chicken chorioallantoic membranes (CAMs) was examined. An animal xenograft model was used to examine the effect of HOXC10 on xenograft angiogenesis or the effect of bevacizumab, a monoclonal antibody against vascular endothelial growth factor A (VEGFA), on HOXC10-overexpressing xenografts. A chromatin immunoprecipitation assay was applied to investigate the mechanism in which HOXC10 regulated VEGFA expression. Results: Overexpressing HOXC10 enhanced the capacity of glioma cells to induce tube formation, migration and proliferation of HUVECs, and neovascularization in CAMs, while silencing HOXC10 had the opposite result. We observed that CD31 staining was significantly increased in tumors formed by HOXC10-overexpressing U251MG cells but reduced in HOXC10-silenced tumors. Mechanistically, HOXC10 could transcriptionally upregulate VEGFA expression by binding to its promoter. Strikingly, treatment with bevacizumab, a monoclonal antibody against VEGFA, significantly inhibited the growth of HOXC10-overexpressing tumors and efficiently impaired angiogenesis. Protein arginine methyltransferase 5 (PRMT5) and WD repeat domain 5 (WDR5), both of which regulate histone post-translational modifications, were required for HOXC10-mediated VEGFA upregulation. Importantly, a significant correlation between HOXC10 levels and VEGFA expression was observed in a cohort of human gliomas. Conclusions: This study suggests that HOXC10 induces glioma angiogenesis by transcriptionally upregulating VEGFA expression, and may represent a potential target for antiangiogenic therapy in gliomas.
P2.03-37 The Efficiency of Octamer-4 Specific Cytotoxic T Cells Induce By CD40-B Cells in Killing Lung Cancer Stem-Like Cells
Authors: X. Zhang, J. Xu, F. Hu, H. Wang, X. Zheng, Y. Zhang, Y. Lou, B. Han
Journal: Journal of Thoracic Oncology (2018)